title: Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study.
abstract: OBJECTIVE
  Cardiac valve calcification (CVC) and coronary artery calcification (CAC) appear to be linked pathogenetically, and both are associated with a poor prognosis among patients with chronic kidney disease on dialysis (CKD-5D). Little is known, however, about factors that affect the progression of CVC and CAC.
  
  
  METHODS
  A post-hoc analysis was performed of the ADVANCE study to assess whether patients with CVC are more prone to CAC progression, and whether CVC predicts the response to different treatments for secondary hyperparathyroidism.
  
  
  RESULTS
  Subjects were randomized to treatment with either cinacalcet and low doses of vitamin D analogs or larger, varying doses of vitamin D. Among 235 subjects, aortic valve or mitral valve calcification was detected in 108 (46%) and 118 (50%), respectively; 69 subjects (29%) had calcification of both valves. CVC was associated both with baseline CAC and CAC progression (p < 0.05). Subjects with aortic valve calcification who were treated with cinacalcet and low doses of vitamin D experienced less progression of CAC than subjects given larger, varying doses of vitamin D (adjusted OR: 0.26; 95% CI: 0.10, 0.64). This effect was greater in subjects with larger CAC burden at baseline.
  
  
  CONCLUSIONS
  The study findings suggest that CVC is a predictor of CAC progression and, potentially, of greater cardiovascular vulnerability. Treatment with cinacalcet combined with low doses of vitamin D slowed the progression of CAC compared to therapy using larger, varying doses of vitamin D.
authors.affiliation: Division of Nephrology, Sant' Anna Hospital, Como, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Bellasi
authors.forename: Maureen
authors.initials: M
authors.lastname: Reiner
authors.forename: Frank
authors.initials: F
authors.lastname: Pétavy
authors.forename: William
authors.initials: W
authors.lastname: Goodman
authors.forename: Juergen
authors.initials: J
authors.lastname: Floege
authors.forename: Paolo
authors.initials: P
authors.lastname: Raggi
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D002114:Calcinosis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D000069449:Cinacalcet; D003331:Coronary Vessels / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005260:Female; D006351:Heart Valves / Q000473:pathology*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000628:therapy*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000493:pharmacokinetics; D011379:Prognosis; D044169:Receptors, Calcium-Sensing / Q000819:agonists; D006435:Renal Dialysis / Q000009:adverse effects*; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D050071:Bone Density Conservation Agents; D009281:Naphthalenes; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D000069449:Cinacalcet